THC Farmaceuticals, Inc. engages in the research and development of cannabis pharmaceutical products. The company is headquartered in Scottsdale, Arizona and currently employs 2 full-time employees. The company went IPO on 2012-08-22. The firm specializes in the discovery, development, and commercialization of novel cannabinoid-based products in dental, ophthalmology and other medical disciplines. The company offers the combination of its proprietary developments with its clinicians and scientists to unlock the therapeutic properties of cannabis and its bioactive compounds. The firm owns clinical research center and cannabidiol (CBD) manufacturing facility in California. Its business plan includes conducting cannabinoids research and development in collaboration with cannabis research centers worldwide with the goal of developing novel and advanced therapeutic methods for the treatment of common medical conditions with cannabis-based therapies and to conduct pre-clinical investigations and randomized, placebo-controlled trials of CBD-based compounds and develop condition-specific medications. The company offers a network of micro vending kiosk systems.
CBDG stock price ended at $0.04 on 星期二, after rising 100.00%
On the latest trading day Dec 30, 2025, the stock price of CBDG rose by 100.00%, climbing from $0.04 to $0.04. Throughout the session, the stock experienced a volatility of 0.00%, with prices fluctuating between a daily low of $0.04 and a high of $0.04. Alongside this price increase, trading volume also rose by 8.4K shares, reflecting strong market interest that may signal continued bullish momentum in the near term. In total, 125 shares were traded, amounting to a market value of approximately $725.2K.